期刊文献+

辛伐他汀和吉非罗齐对高脂血症伴骨量减少患者骨代谢和骨密度的影响 被引量:4

Effects of Simvastatin and Gemfibrozil on bone metabolism and bone mineral density in patients with hypercholesterolemia and osteopenia
下载PDF
导出
摘要 目的观察辛伐他汀和吉非罗齐对高胆固醇血症伴骨量减少患者骨代谢指标及骨密度的影响。方法高脂血症合并骨量减少患者128例,分两组后分别予以辛伐他汀和吉非罗齐治疗,并在治疗前及治疗后分别检测血脂、骨吸收标志物血清I型胶原羧基末端肽(sCTX)、骨形成标志物总骨Ⅰ型前胶原N端肽(P1NP)和桡骨远端骨密度(BMD)。结果辛伐他汀组平均治疗周期(10.24±1.89)个月,治疗后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)明显降低(P<0.05),同时sCTX降低(P<0.01),P1NP增高(P<0.05),BMD增加(P<0.01),而吉非罗齐治疗后虽TC、TG、LDL-C明显降低(P<0.05)但sCTX、P1NP和BMD无明显变化。结论较大剂量辛伐他汀具有抑制骨吸收、增强骨形成和增加BMD的作用,可能与血脂水平降低无关。 Objective To compare the effects of Simvastatin and Gemfibrozil on bone metabolism and bone mineral density(BMD) in patients with hypercholesterolemia and osteopenia.Methods Totally 128 with hypercholesterolemia and osteopenia were divided into Simvastatin group and Gemfibrozil group.The blood lipid,bone absorption maker sCTX,bone formation makers P1NP and BMD at distal end of radius were measured before and after the treatment with Simvastatin and Gemfibrozil.Results The total cholesterol(TC),total triglycerides(TG) and low density lipoprotein cholesterol(LDL-C) were obviously lowered in both group(P0.05).The sCTX was lowered(P0.01),P1NP was raised(P0.05)and BMD was increased(P0.01)in Simvastatin group but no change of sCTX,P1NP and BMD was observed in Gemfibrozil group.Conclusion Moderate to high dosage of simvastatin is beneficial to inhibiting bone absorption,enhancing bone formation and increasing BMD and it may in no relation with lowered level of blood lipid.
出处 《局解手术学杂志》 2011年第1期57-59,共3页 Journal of Regional Anatomy and Operative Surgery
关键词 辛伐他汀 骨代谢 骨密度 高脂血症 Simvastatin bone metabolism bone mineral density hypercholesterolemia
  • 相关文献

参考文献9

  • 1Yamashita M,Otsuka F,Mukai T,et al.Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic protein-2 induced osteoblast differentiation by regulating Smad signaling and RasⅡ Rhomitogen-activated protein kinase pathway[J].Endocrinol,2008,196(5):601 -613.
  • 2朴俊红,庞莲萍,刘忠厚,向青,苏南,潘子昂,郭亦超,李芳芳,李扶刚,刘京萍,陈仲景,王晓敏,扈英伟,张燕晴,王晓红,程晓光.中国人口状况及原发性骨质疏松症诊断标准和发生率[J].中国骨质疏松杂志,2002,8(1):1-7. 被引量:287
  • 3McFarlane SI,Muniyappa R,Francisco R,et al.Clinical review 145:pleiotropic effects of statins:lipid reduction and beyond[J].Clin Endocrinol Metab,2002,87(9):1451-1458.
  • 4张志梅,李玉坤.他汀类药物对骨代谢影响的研究进展[J].国际药学研究杂志,2009,36(2):100-104. 被引量:8
  • 5张英男,朱晓琳,高萍.辛伐他汀对血脂异常的男性患者骨转化及骨密度的影响[J].中国骨质疏松杂志,2008,14(6):414-415. 被引量:5
  • 6丁跃有,蒋世峰,康彬,江嘉义,徐伟民.辛伐他汀对老年高胆固醇血症患者骨密度和骨转换影响的研究[J].中国老年学杂志,2009,29(4):457-459. 被引量:4
  • 7Rosenson RS,Tangney CC,Langman CB,et al.Short-term reduction in bone markers with high-dose simvastatin[J].Osteoporos Int,2005,16(9):1272-1276.
  • 8Somlak C,Suthee R,Somponge S,et al.Effects of statins vs.non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia[J].Bone,2010,46 (6):1011-1015.
  • 9Bjamason NH,Riis B J,Christiansen C.The effect of fluvastatin on parameters of bone remodeling[J].Osteoporos Int,2001,12 (5):380 -384.

二级参考文献43

共引文献299

同被引文献62

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部